Absence of disease transmission risk allows the Kerecis™ fish skin to be processed in a gentle manner preserving structure and content. Kerecis™ Omega3 is therefore more similar to human skin than any other skin substitute. This has relevance in wound closure as shown by multiple clinical trials, including a double-blind, comparative randomized control trial (N=162) where fish skin favorably compared with mammalian skin substitutes. Furthermore fish skin is rich of Omega3 that possesses multiple health benefits.

Kerecis™ has developed the unique, patented Kerecis™ Omega3 fish-skin technology, where intact fish skin is used for tissue regeneration by transplantation.

The transplantation technology is used to reconstruct the skin in for example burn wounds and chronic wounds as well as in surgical applications.

Kerecis™ Omega3 Wound is approved by the FDA and multiple other regulatory agencies and is covered by Medicare in all the 50 U.S. states.

Damage to the intercelluar material of the skin's corneal layer causes dryness and inflammation.

mOmega3™ are proprietary, fish-sourced fatty acids, that restore the health of the corneal layer of the skin in a natural manner benefitting a multitude of abnormal skin conditions.

The mOmega3™ product range covers indications such as psoriasis, eczema, dermatitis, keratosis pilaris and pseudofolliculitis.